stocks logo

TECH

Bio-Techne Corp
$
52.020
-1.27(-2.383%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
53.890
Open
53.710
VWAP
52.32
Vol
1.81M
Mkt Cap
8.16B
Low
51.740
Amount
94.50M
EV/EBITDA(TTM)
25.36
Total Shares
157.58M
EV
8.34B
EV/OCF(TTM)
31.51
P/S(TTM)
6.90
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
310.40M
+4.5%
0.472
+12.42%
299.58M
+3.5%
0.439
+4.61%
315.14M
+2.95%
0.499
+1.82%
Estimates Revision
The market is revising Downward the revenue expectations for Bio-Techne Corporation (TECH) for FY2025, with the revenue forecasts being adjusted by -0.87% over the past three months. During the same period, the stock price has changed by 9.49%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.87%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.14%
In Past 3 Month
Stock Price
Go Up
up Image
+9.49%
In Past 3 Month
10 Analyst Rating
up Image
30.93% Upside
Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is 68.11 USD with a low forecast of 51.00 USD and a high forecast of 90.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
3 Hold
0 Sell
Moderate Buy
up Image
30.93% Upside
Current: 52.020
sliders
Low
51.00
Averages
68.11
High
90.00
TD Cowen
NULL
to
Buy
initiated
$65
2025-07-09
Reason
TD Cowen initiated coverage of Bio-Techne with a Buy rating and $65 price target. The pullback and multiple de-rating look overdone, even though macro risks have weighed on shares, the analyst tells investors in a research note. The current valuation doesn't reflect the strong organic growth and margin opportunity where Bio-Techne addresses several of the highest growth areas in Tools with strong product offerings, TD Cowen adds.
Wells Fargo
Brandon Couillard
Overweight
initiated
$59
2025-05-30
Reason
Argus
Buy
downgrade
$90 -> $65
2025-05-30
Reason
Argus lowered the firm's price target on Bio-Techne to $65 from $90 but keeps a Buy rating on the shares. Bio-Techne's endmarkets have improved, but it now faces multiple headwinds in the form of trade tariffs and cuts in funding to academic and government customers, the analyst tells investors in a research note. Given the changing dynamics for tariffs and NIH funding however, these headwinds may well be temporary and the improving end markets may be more sustainable, the firm added.
UBS
Buy
downgrade
$95 -> $70
2025-05-09
Reason
Stifel
Hold
downgrade
$75 -> $60
2025-05-08
Reason
RBC Capital
Sector Perform
downgrade
$72 -> $63
2025-05-08
Reason
RBC Capital lowered the firm's price target on Bio-Techne to $63 from $72 and keeps a Sector Perform rating on the shares. The company reported a 5c beat in Q3 driven by margin outperformance, and painted a much brighter picture of the near-term outlook in LST end-markets than peers, the analyst tells investors in a research note. RBC adds however that navigating the current NIH and tariff environment will be key in de-risking FY26 numbers.

Valuation Metrics

The current forward P/E ratio for Bio-Techne Corp (TECH.O) is 26.08, compared to its 5-year average forward P/E of 43.28. For a more detailed relative valuation and DCF analysis to assess Bio-Techne Corp 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
43.28
Current PE
26.08
Overvalued PE
53.39
Undervalued PE
33.17

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
30.36
Current EV/EBITDA
19.73
Overvalued EV/EBITDA
37.02
Undervalued EV/EBITDA
23.70

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
11.47
Current PS
6.63
Overvalued PS
14.52
Undervalued PS
8.42

Financials

Annual
Quarterly
FY2025Q3
YoY :
+4.20%
316.18M
Total Revenue
FY2025Q3
YoY :
-43.21%
40.88M
Operating Profit
FY2025Q3
YoY :
-53.96%
22.59M
Net Income after Tax
FY2025Q3
YoY :
-54.84%
0.14
EPS - Diluted
FY2025Q3
YoY :
-51.98%
31.00M
Free Cash Flow
FY2025Q3
YoY :
+0.70%
67.90
Gross Profit Margin - %
FY2025Q3
YoY :
-16.08%
18.26
FCF Margin - %
FY2025Q3
YoY :
-55.84%
7.14
Net Margin - %
FY2025Q3
YoY :
-37.37%
5.85
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
63.7K
USD
1
3-6
Months
122.7K
USD
1
6-9
Months
1.0M
USD
1
0-12
Months
1.1M
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 308.81% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
4.5K
Volume
1
6-9
Months
1.1M
Volume
8
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
1.6M
Volume
Months
6-9
2
397.6K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
16.0K
USD
2
3-6
Months
16.0K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
6
48.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

TECH News & Events

Events Timeline

2025-07-15 (ET)
2025-07-15
07:04:27
Bio-Techne and Spear Bio partner for ultrasensitive biomarker detection
select
2025-06-24 (ET)
2025-06-24
07:02:26
Bio-Techne, USP collaborate to develop monoclonal antibody and gene therapy
select
2025-05-08 (ET)
2025-05-08
09:32:26
Bio-Techne, Kytopen collaborate on integrated cellular engineering workflow
select
Sign Up For More Events

News

8.0
07-17NASDAQ.COM
Interesting TECH Put And Call Options For September 19th
9.5
07-17PRnewswire
Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results
7.5
07-16NASDAQ.COM
Spear Bio Partners With Bio-Techne To Expand Access To UltraSensitive Neuro Biomarker Assays
Sign Up For More News

FAQ

arrow icon

What is Bio-Techne Corp (TECH) stock price today?

The current price of TECH is 52.02 USD — it has decreased -2.38 % in the last trading day.

arrow icon

What is Bio-Techne Corp (TECH)'s business?

arrow icon

What is the price predicton of TECH Stock?

arrow icon

What is Bio-Techne Corp (TECH)'s revenue for the last quarter?

arrow icon

What is Bio-Techne Corp (TECH)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Bio-Techne Corp (TECH)'s fundamentals?

arrow icon

How many employees does Bio-Techne Corp (TECH). have?

arrow icon

What is Bio-Techne Corp (TECH) market cap?